Alnylam Pharmaceuticals Executive and Leadership Team

Yvonne Greenstreet, the Chief Executive Officer at Alnylam Pharmaceuticals, directs the overarching corporate strategy and long-term vision for RNAi therapeutic innovation. Greenstreet oversees the transition of research programs into commercialized products like ONPATTRO and AMVUTTRA. By managing high-level partnerships with global entities such as Roche and Regeneron, the Chief Executive Officer ensures the company maintains a competitive edge in the biopharmaceutical sector. This leadership role involves constant engagement with the Board to align clinical development milestones with shareholder expectations. Through rigorous oversight of the entire product pipeline, Greenstreet drives the expansion of therapeutic applications into new disease areas like hypertension and Alzheimer's. Ultimately, Yvonne Greenstreet secures the financial and operational health of the organization while fostering a culture of scientific excellence that defines the company's market position.

Jeff Poulton, the Chief Financial Officer at Alnylam Pharmaceuticals, manages the fiscal health and capital allocation strategies necessary to support intensive drug discovery efforts. Poulton oversees financial planning, investor relations, and the budgetary requirements for phase 3 clinical trials. By analyzing market trends and revenue streams from products like GIVLAARI and OXLUMO, the Chief Financial Officer ensures the company maintains sufficient liquidity for ongoing research. This role involves coordinating with external partners to optimize license agreements and maximize the value of the existing portfolio. Through disciplined financial modeling, Jeff Poulton supports the scaling of operations across North American and international markets. Ultimately, Poulton provides the economic framework that allows the organization to pursue complex scientific breakthroughs while maintaining sustainable growth and long-term profitability for all stakeholders.

Vasant Jadhav, the Chief Technology Officer at Alnylam Pharmaceuticals, architects the technical infrastructure and scientific platforms required for advanced RNA interference research. Jadhav oversees the development of proprietary delivery mechanisms that enable the efficacy of therapeutics targeting hepatic and neurological conditions. By directing the integration of new technologies into the drug discovery pipeline, the Chief Technology Officer ensures the company remains at the forefront of genetic medicine. This leadership role involves collaborating with research teams to refine the molecular design of candidates like ALN-APP and Zilebesiran. Through the application of cutting-edge computational and biological tools, Vasant Jadhav accelerates the transition from laboratory discovery to clinical application. Ultimately, Jadhav maintains the technological superiority of the platform, ensuring the company continues to deliver innovative solutions for patients with high unmet medical needs.

Shweta Randeria, the Chief Marketing Officer at Alnylam Pharmaceuticals, drives the commercialization strategy for the company's portfolio of approved RNAi therapeutics. Randeria oversees the development of market access programs and educational initiatives for healthcare providers treating rare diseases. By analyzing patient demographics and regional market dynamics, the Chief Marketing Officer ensures that products like AMVUTTRA reach the populations requiring treatment most urgently. This role involves coordinating with sales teams to communicate the clinical benefits of the company's innovative drug pipeline. Through targeted outreach and brand positioning, Shweta Randeria expands the footprint of the company in both domestic and global markets. Ultimately, Randeria secures the successful adoption of new therapies by demonstrating the value of RNAi technology to the medical community and ensuring patients gain access to life-changing treatments.

Danielle Dougherty, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, executes the operational workflows that support the commercial marketing division. Dougherty oversees the administrative alignment between marketing leadership and the broader sales organization to ensure consistent messaging for products like ONPATTRO. By managing internal project timelines and resource allocation, the Manager, Chief Marketing Officer Management facilitates the efficient execution of promotional campaigns. This role involves streamlining communication channels to ensure that the Chief Marketing Officer receives accurate data regarding market performance and regional adoption rates. Through meticulous coordination of departmental activities, Danielle Dougherty enables the marketing team to focus on strategic growth initiatives. Ultimately, Dougherty optimizes the internal processes that allow the company to effectively communicate the clinical impact of its therapeutic portfolio to diverse healthcare audiences.

Carlo Cristobal, the Head To of & Ttr Franchise Chief of Staff (US) at Alnylam Pharmaceuticals, coordinates the strategic operations of the transthyretin-mediated amyloidosis franchise. Cristobal oversees the cross-functional alignment of clinical, regulatory, and commercial teams focused on the TTR portfolio. By managing the day-to-day execution of franchise priorities, the Head To of & Ttr Franchise Chief of Staff (US) ensures that development milestones for vutrisiran and other related therapies remain on schedule. This role involves facilitating communication between the US leadership team and global stakeholders to ensure operational consistency. Through the management of complex project dependencies, Carlo Cristobal drives the efficiency of the franchise's market entry and patient support programs. Ultimately, Cristobal ensures the TTR franchise maintains its leadership position by fostering seamless collaboration across all internal departments.

Melissa McLaughlin, the Chief Human Resources Officer at Alnylam Pharmaceuticals, directs the talent acquisition and organizational development strategies that support the company's scientific mission. McLaughlin oversees the recruitment of specialized researchers and commercial experts necessary to advance the RNAi pipeline. By implementing performance management systems and professional development programs, the Chief Human Resources Officer ensures the workforce remains highly skilled and motivated. This role involves fostering an inclusive corporate culture that attracts top-tier talent from the global biopharmaceutical industry. Through the alignment of human capital initiatives with business objectives, Melissa McLaughlin supports the scaling of operations as the company enters new therapeutic areas. Ultimately, McLaughlin builds the organizational capacity required to sustain long-term innovation and operational excellence across all departments within the company.

Bryan Supran, the Chief Legal Officer at Alnylam Pharmaceuticals, manages the legal and regulatory framework governing the company's intellectual property and strategic collaborations. Supran oversees the negotiation of complex license agreements with partners like Novartis and Vir Biotechnology. By ensuring compliance with international healthcare regulations, the Chief Legal Officer protects the company's interests during the development and commercialization of novel therapeutics. This role involves providing counsel on patent strategy to safeguard the proprietary RNAi technology platform. Through the mitigation of legal risks and the management of corporate governance, Bryan Supran enables the organization to pursue aggressive growth and partnership opportunities. Ultimately, Supran provides the essential legal foundation that allows the company to navigate the highly regulated pharmaceutical landscape while securing the long-term value of its scientific innovations.